BI Asset Management Fondsmaeglerselskab A S Purchases 17,678 Shares of Insulet Corporation $PODD

Key Points

• BI Asset Management Fondsmaeglerselskab A S boosted its Insulet stake by 137.5% in Q4, buying 17,678 additional shares and bringing its total holding to 30,534 shares worth about $8.68 million.
• Several other large institutions also increased or initiated positions in Insulet, including Vanguard, Geode Capital, Norges Bank, and Goldman Sachs, highlighting continued institutional interest in the stock.
• Insulet beat quarterly earnings and revenue expectations, but analysts have recently cut price targets; Wall Street still carries a Moderate Buy consensus with a $252.04 average price target.

BI Asset Management Fondsmaeglerselskab A S increased its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 137.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 30,534 shares of the medical instruments supplier's stock after acquiring an additional 17,678 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Insulet were worth $8,679,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Insulet by 1.0% in the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier's stock valued at $2,715,651,000 after buying an additional 87,845 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier's stock valued at $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Norges Bank acquired a new stake in shares of Insulet in the fourth quarter valued at approximately $300,794,000. Goldman Sachs Group Inc. raised its holdings in shares of Insulet by 1.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 768,066 shares of the medical instruments supplier's stock valued at $218,315,000 after purchasing an additional 10,254 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Insulet by 0.5% in the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier's stock valued at $218,945,000 after purchasing an additional 3,618 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Sanford C. Bernstein lowered their price objective on shares of Insulet from $330.00 to $200.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $280.00 price objective on shares of Insulet in a report on Wednesday, May 27th. JPMorgan Chase & Co. decreased their price objective on Insulet from $340.00 to $275.00 and set an "overweight" rating for the company in a report on Thursday, May 7th. Jefferies Financial Group lowered their target price on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Finally, Rothschild & Co Redburn reissued a "neutral" rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $252.04.

Insider Activity

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.36% of the company's stock.

Insulet Stock Performance

NASDAQ PODD opened at $153.22 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm's fifty day moving average price is $175.73 and its two-hundred day moving average price is $238.90. Insulet Corporation has a 1 year low of $140.63 and a 1 year high of $354.88. The firm has a market capitalization of $10.61 billion, a P/E ratio of 35.63, a price-to-earnings-growth ratio of 1.21 and a beta of 1.13.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to analysts' expectations of $729.89 million. During the same period in the previous year, the business posted $1.02 earnings per share. The company's revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts anticipate that Insulet Corporation will post 6.46 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.